Astria Therapeutics, Inc. Quarterly Deferred Tax Assets, Valuation Allowance in USD from Q4 2014 to Q4 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
Astria Therapeutics, Inc. quarterly Deferred Tax Assets, Valuation Allowance history and growth rate from Q4 2014 to Q4 2023.
  • Astria Therapeutics, Inc. Deferred Tax Assets, Valuation Allowance for the quarter ending December 31, 2023 was $125M, a 20.4% increase year-over-year.
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q4 2023 $125M +$21.1M +20.4% Dec 31, 2023 10-K 2024-03-04
Q4 2022 $104M +$14.6M +16.3% Dec 31, 2022 10-K 2024-03-04
Q4 2021 $89.1M +$11.2M +14.4% Dec 31, 2021 10-K 2023-03-22
Q4 2020 $77.9M +$11.1M +16.6% Dec 31, 2020 10-K 2022-03-10
Q4 2019 $66.8M +$7.58M +12.8% Dec 31, 2019 10-K/A 2021-04-19
Q4 2018 $59.2M +$7.76M +15.1% Dec 31, 2018 10-K 2020-03-10
Q4 2017 $51.4M -$8.43M -14.1% Dec 31, 2017 10-K 2019-03-14
Q4 2016 $59.8M +$14.7M +32.5% Dec 31, 2016 10-K 2018-03-15
Q4 2015 $45.2M +$13.6M +43.3% Dec 31, 2015 10-K 2017-03-16
Q4 2014 $31.5M Dec 31, 2014 10-K 2016-03-15
* An asterisk sign (*) next to the value indicates that the value is likely invalid.